Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

Authors

Wilson X. Wang, Washington University School of Medicine in St. Louis
Dan Spiegelman, Washington University School of Medicine in St. Louis
P. Kumar Rao, Washington University School of Medicine in St. Louis
Andria L. Ford, Washington University School of Medicine in St. Louis
Rajendra S. Apte, Washington University School of Medicine in St. Louis

Journal

Journal of Clinical Investigation

Publication Date

5-7-2024

Volume

134

Issue

12

First Page

e180916

Document Type

Open Access Publication

DOI

10.1172/JCI180916

Rights and Permissions

Wang WX, Spiegelman D, Rao PK, Ford AL, Apte RS. Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study. J Clin Invest. 2024 May 7;134(12):e180916. doi: 10.1172/JCI180916. © 2024, Wang et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Recommended Citation

Wang, Wilson X.; Spiegelman, Dan; Rao, P. Kumar; Ford, Andria L.; and Apte, Rajendra S., "Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study." Journal of Clinical Investigation. 134, 12. e180916 (2024).
https://digitalcommons.wustl.edu/oa_4/3894

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.